论文部分内容阅读
免疫策略咨询委员会(Strategic Advisory Group of Experts,SAGE)于2012年11月6~8日在瑞士日内瓦召开会议。本文对会议决议、结论和建议进行了总结。1世界卫生组织(World Health Organization,WHO)免疫、疫苗和生物制品部门报告2011年,全球90%的儿童接种了第一剂含百日咳-白喉-破伤风成分疫苗(Diphtheria-Tetanus-Pertussis Containing Vaccine,DTP),但在一些国家仍存在第一剂DTP(DTP1)和第三剂DTP(DTP3)接种较高的脱漏率,造成全球DTP3估算接种率仅为83%。194个WHO成员国中,有64个国家的DTP3接种率
The Strategic Advisory Group of Experts (SAGE) met from 6 to 8 November 2012 in Geneva, Switzerland. This article summarizes the resolutions, conclusions and recommendations of the conference. 1 World Health Organization (WHO) Immunization, Vaccines and Biological Products Sector Reports In 2011, 90% of children worldwide received the first Diphtheria-Tetanus-Pertussis Containing Vaccine However, in some countries there is still a high rate of leakage of DTP1 and DTP3, resulting in an estimated global DTP3 coverage of only 83%. Of the 194 WHO member countries, 64 have DTP3 coverage